ATLANTA, GA – – (Businesswire – August 29, 2017) – – Holzer & Holzer, LLC is investigating whether Acorda Therapeutics, Inc. (“Acorda” or the “Company”) (NASDAQ: ACOR) complied with the federal securities laws. On August 29, 2017, Acorda announced that the FDA had rejected the Company’s New Drug Application (“NDA”) for INBRIJA, an investigational Parkinson’s treatment drug, because the NDA was not sufficiently completed. Acorda stock price declined significantly following the announcement. If you purchased Acorda common stock and suffered a loss on that investment, you are encouraged to visit the firm’s website at www.holzerlaw.com to receive additional information about your legal rights. You can also contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or call the firm by toll-free telephone at (888) 508-6832 for more information.